Skip to main content

Dx Focus Sep 9, 2010: Clinical and Regulatory PCR and Nucleic Acid Testing News

Premium

Myconostica said this week that its MycAssay Aspergillus test has received the CE mark for detecting Aspergillus spp. DNA in serum.

MycAssay Aspergillus is a molecular diagnostic assay designed to be used by laboratory professionals, and the results of the test aid physicians in diagnosing patients suspected of having an infection caused by Aspergillus, according to Manchester, UK-based Myconostica.

MycAssay Aspergillus previously received the CE mark for respiratory samples, meaning that the test is now CE marked for all major sample types. There are a number of high-risk patient groups for whom it is difficult to obtain respiratory samples, Myconostica said.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.